# Nuclide record radiomedix (company). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/companies/radiomedix/>
  a schema:Organization ;
  nuclide:kind "company" ;
  schema:identifier "radiomedix" ;
  schema:name "RadioMedix"@en ;
  schema:description "RadioMedix is developing AlphaMedix (212Pb-DOTAMTATE) with Orano Med, the first targeted alpha therapy to receive FDA Breakthrough designation."@en ;
  schema:url <https://nuclide.cc/companies/radiomedix/>, <https://www.radiomedix.com> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://www.sanofi.com/en/media-room/press-releases/2024/2024-09-12-05-00-00-2944919> ;
  schema:addressCountry "US" ;
  nuclide:related <https://nuclide.cc/isotopes/pb-212/> ;
  nuclide:indications <https://nuclide.cc/indications/neuroendocrine/> ;
  nuclide:technologies <https://nuclide.cc/technologies/targeted-alpha-therapy/> ;
  nuclide:targets <https://nuclide.cc/targets/sstr2/> ;
  nuclide:companies <https://nuclide.cc/companies/orano-med/> .